Blog
RSS FeedPosted by Michael Wonder on 20 Apr 2021
NICE’s five year strategy sets a ‘positive vision for the future’
20 April 2021 - The pharma industry has responded to the NICE new five year strategy, announced yesterday. ...
Posted by Michael Wonder on 20 Apr 2021
NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer
20 April 2021 - NICE has today published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund for ...
Posted by Michael Wonder on 15 Apr 2021
NICE publishes draft guidance on new use for fenfluramine hydrochloride
15 April 2021 - The Department of Health and Social Care has asked NICE to produce guidance on using fenfluramine hydrochloride ...
Posted by Michael Wonder on 15 Apr 2021
Alexion's pricey Ultomiris wins backing from England's cost watchdogs thanks to confidential discount
15 April 2021 - Alexion has added a nice piece to Ultomiris’ growth potential ahead of its planned merger with ...
Posted by Michael Wonder on 08 Apr 2021
NICE publishes guidance on nivolumab - ipilumumab combo
8 April 2021 - The Department of Health and Social Care has asked NICE to produce guidance on using nivolumab with ...
Posted by Michael Wonder on 07 Apr 2021
Thousands to benefit from five minute breast cancer treatment
6 April 2021 - NHS England is rolling out an injection that dramatically cuts the amount of time breast cancer ...
Posted by Michael Wonder on 06 Apr 2021
NHS prescription charges to rise in price today
1 April 2021 - Millions of people will pay more for prescriptions from today as new rates come into force across ...
Posted by Michael Wonder on 06 Apr 2021
NICE backs restricted use of Ondexxya
6 April 2021 - NHS cost regulators have backed funding for Alexion's Ondexxya (andexanet alfa) to reverse anti-coagulation of the ...
Posted by Michael Wonder on 31 Mar 2021
NICE publishes guidance on new use for Kisqali
31 March 2021 - NICE has published an evidence base recommendation on ribociclib succinate (Kisqali) for the treatment of adults ...
Posted by Michael Wonder on 31 Mar 2021
NICE recommends Sobi’s Kineret for first-line use in Still’s disease
31 March 2021 - NICE has approved Kineret (anakinra) to treat systemic juvenile idiopathic arthritis in people aged eight months ...
Posted by Michael Wonder on 30 Mar 2021
Phenylketonuria sufferer has new hope for wonder drug after Government responds to plea
30 March 2021 - A teenager desperate to get a life-changing drug has been thrown a glimmer of hope by ministers. ...
Posted by Michael Wonder on 30 Mar 2021
NICE methods and process review aims to create fertile ground for innovation
29 March 2021 - The way NICE reviews new medicines is about to go through its biggest change in years – ...
Posted by Michael Wonder on 24 Mar 2021
NICE publishes draft guidance for secukinumab (Cosentyx)
24 March 2021 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 24 Mar 2021
NICE publishes draft guidance for ixekizumab (Taltz)
24 March 2021 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 22 Mar 2021
Triple therapy recommended by NICE for patients with multiple myeloma
22 March 2021 - The therapy has been recommended after a confidential discount was agreed between NHS England and the drug ...